AzTrials
AzTrials

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2NCT02967679

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

A Phase 2 study testing MD1003 in people with Chronic Inflammatory Demyelinating Polyneuropathy and Peripheral Neuropathy, run by MedDay Pharmaceuticals SA at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects. Read more about this study

Who is it for?
Ages 20 to 85 years
What is being tested?
MD1003
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteFrance
Study dates
5 Dec 2016to 18 Mar 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and female aged between 20 and 85 years.
  • Patients fulfilling one of the following diagnosis:
  • Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
  • Five patients with proven genetic diagnosis of CMT1a or CMT1b
  • Five patients with anti-MAG polyneuropathy.
  • Electrophysiological parameters worsening for the past 3 years
Show all 11Show fewer
  • Available EMG record, performed during the past 6 months to assess variability of NCV parameters
  • Signed and dated written informed consent to participate in the study in accordance with local regulations
  • Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
  • In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study.
  • Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination.

Who cannot join

  • Any general chronic handicapping disease other than peripheral neuropathy
  • Impossibility to perform the 10 meters walking test
  • Impossibility to assess electrophysiological parameters
  • Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer,
  • Patients with hypersensitivity to MD1003 excipients (lactose)
  • Laboratory tests out of normal range according to the reference laboratory values. Deviations may be accepted if considered by the investigator as not clinically significant with regards to the study continuation,
Show all 11Show fewer
  • Patients with history or presence of alcohol abuse or drug addiction,
  • Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve.
  • Any new medication for neuropathy initiated less than 3 months prior to inclusion. For CIDP patients, relapse in the past 3 months before inclusion.
  • Not easily contactable by the investigator in case of emergency or not capable to call the investigator
  • Subjects without effective contraception

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital Henri Mondor, Créteil, France

    Créteil, 94010

Other trials in France

About this study

Official title: SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Being tested
MD1003
Keywords
Neuropathy, Demyelinating polyradiculoneuropathy
Medical subject headings
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Peripheral Nervous System Diseases, Charcot-Marie-Tooth Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MD1003Drug

    Also called High Dose Biotin

Study groups in NCT02967679
Study groupRoleWhat they receive
MD1003ExperimentalMD1003 100mg capsules, 1 capsule tid for 48 weeks
Receives: Drug: MD1003

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Motor Nerve Conduction Velocity (m/Sec)

    Absolute change from baseline at Week 48.

    Measured: 48 weeks

  2. Distal Latency (Msec)

    Absolute change from baseline at Week 48.

    Measured: 48 weeks

  3. F Wave Latency (Msec)

    Absolute change from baseline at Week 48.

    Measured: 48 weeks

  4. Length of Motor Nerve Potential

    Absolute change from baseline at W48.

    Measured: 48 weeks

Secondary outcomes (12)
  1. ONLS (Overall Neuropathy Limitations Scale)

    The ONLS focuses on upper and lower limb functions, and consists of a checklist for interviewing patients. It is scored from 0 to 5 on the upper limb section and from 0 to 7 on the lower limb section. A score of 0 indicates no limitations (the ceiling of the scale) and a score of 5 or 7 indicates no purposeful movement. Absolute change from baseline at week 48.

    Measured: 48 weeks

  2. Change From Baseline at Week 48 for Timed 10-meter Walk Test

    Absolute change from baseline at week 48. The patient is instructed to walk at normal pace for 10 meters. Start and stop of performance time coincides with the toes of the leading foot crossing the 2-m mark and the 8-m mark, respectively. From these data, the speed may be calculated by dividing the middle 6 m by the time (in seconds).

    Measured: 48 weeks

  3. Absolute Change From Baseline at Week 48 for Medical Research Council (MRC) Subscore (Total Muscle) and Total Score

    MRC score assessed in 19 muscles.

    The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.

    The patient's effort is graded on a scale of 0-5:

    Grade 5: Muscle contracts normally against full resistance. Grade 4: Muscle strength is reduced but muscle contraction can still move joint against resistance.

    Grade 3: Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner's resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side.

    Grade 2: Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.

    Grade 1: Only a trace or flicker of movement is seen or felt in the muscle or fasciculations are observed in the muscle.

    Grade 0: No movement is observed.

    Measured: 48 weeks

  4. INCAT Sensory Sum Score (ISS)

    This sensory scale comprises pin prick and vibration sense plus a two point discrimination value in the arms and legs, and ranges from 0 ("normal sensation") to 20 ("most severe sensory deficit"). Absolute change from baseline at week 48.

    Measured: 48 weeks

  5. 6-minute Walk Test

    The 6MWT is a practical simple test that requires a 30 m (100-ft) hallway. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. Absolute change from baseline at week 48.

    Measured: 48 weeks

  6. Posturography Score

    Computerized dynamic posturography (CDP) is a non-invasive specialized clinical assessment technique used to quantify the central nervous system adaptive mechanisms (sensory, motor and central) involved in the control of posture and balance, both in normal and abnormal conditions. Absolute change of speed in spontaneous speed condition from baseline at week 48.

    Measured: 48 weeks

  7. Excitability Testing: Supernormality (%)

    Nerve excitability testing is a non-invasive approach in investigating the pathophysiology of peripheral nerve disorders, which determines the electrical properties of the nerve membrane at the site of stimulation. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). During the 10-30 ms following the end of the refractory period, the axon increases its excitability and the nerve fiber is more easily excited (the supernormal period). Depolarization of the node of Ranvier excites the adjacent internodes, which then charge with electric current as capacitors. Supernormality depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.

    Measured: 48 weeks

  8. Strength-duration Time Constant (ms)

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    Strength-duration Time Constant (ms) is a measurement of excitability, defined as the duration of the stimulus that has twice the strength of the rheobase current (see below). The lower the rheobase is, the higher is the Strenght duration time constant. Accordingly, higer values of SDTC are associated with better outcome.

    Measured: 48 weeks

  9. Rheobase (mA)

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    Rheobase is the minimal strength of an electrical stimulus of infinitely long duration that is able to cause excitation. Low values are associated with better outcome (the nerve becomes more excitable).

    Measured: 48 weeks

  10. Refractoriness (%)

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline to week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.

    Measured: 48 weeks

  11. Minimum Absolute Refractory Period (ms).

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.

    Measured: 48 weeks

  12. Maximum Absolute Refractory Period (ms).

    This secondary outcome measure is an electrophysiological testing endpoint. Absolute change from baseline at week 48.

    After a nerve fiber is depolarized, a sequence of excitability changes, called the 'recovery cycle', occurs before the membrane potential returns to its resting stage. This cycle includes phases in which the nerve excitability is decreased ('refractory period' or increased ('supernormal period'). Refractoriness depends on many factors and its interpretation is therefore not univoqual. Data were provided for information only.

    Measured: Week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2016 (estimated)
  2. Study start5 Dec 2016
  3. Primary completion18 Mar 2019
  4. Study completion18 Mar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02967679
Sponsor's protocol ID
MD1003CT2015-01 SERENDEM
Status last verified
Oct 2020
First submitted
8 Nov 2016
Last updated
2 Nov 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Creange A, Hutin E, Sedel F, Le Vigouroux L, Lefaucheur JP. High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study. BMC Neurol. 2023 Oct 30;23(1):389. doi: 10.1186/s12883-023-03440-y.

    PubMed 37899433

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing MD1003 in people with Chronic Inflammatory Demyelinating Polyneuropathy and Peripheral Neuropathy, run by MedDay Pharmaceuticals SA at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Nov 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Motor Nerve Conduction Velocity (m/Sec) (time frame: 48 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02967679, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in